wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q36462972-F77CB596-F1D5-4361-B591-8CD9E3E8347E
Q36462972-F77CB596-F1D5-4361-B591-8CD9E3E8347E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36462972-F77CB596-F1D5-4361-B591-8CD9E3E8347E
A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer.
P2860
Q36462972-F77CB596-F1D5-4361-B591-8CD9E3E8347E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36462972-F77CB596-F1D5-4361-B591-8CD9E3E8347E
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
9d2f3b9e898d0a5a58e9575217883d9a878fe620
P2860
Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials.